The role of macrophages in the pathogenesis of inflammatory bowel disease

YR MAHIDA MD, MRCP

Macrophages are derived predominantly from circulating monocytes which migrate into tissues. The functions of these cells can be divided broadly into three categories. First, they have a large capacity to produce a variety of molecules with a broad range of biological activities. Secondly, they can process and present antigens to T cells to initiate immunological responses. Thirdly, they are also highly phagocytic cells capable of ingesting microbes and their products as well as other molecules.

There is an increase in the mucosal population of macrophages in inflammatory bowel disease (IBD) which, in the form of granulomata, are particularly prominent in Crohn's disease. There is much less information on human intestinal macrophages than other intestinal cell populations and some of the studies on these cells in normal individuals and IBD patients are reviewed. In the intestine, these cells are a heterogeneous population which have been studied in situ in tissue sections; subsequently functional studies have been performed on isolated cells.
STUDIES ON MACROPHAGES IN SITU IN NORMAL BOWEL

Peyer's patches: Immune responses in the gut are thought to be initiated in Peyer's patches and macrophages are likely to be involved in this process. Studies using monoclonal antibodies and histochemical stains have identified subpopulations of these cells in these regions (1). A distinct subpopulation is present in the dome region, close to the surface epithelium, in a site where they are likely to encounter antigens taken up by microfold cells. Other subsets are present in the germinal centre and interfollicular region. The latter cells are phenotypically similar to interdigitating cells of the paracortical T-dependent regions of lymph nodes.

**Lamina propria:** Macrophage heterogeneity is also seen in the lamina propria of normal small and large intestine (2,3). Macrophages below the surface epithelium tend to be large and round, with strong acid phosphatase activity, whereas those in deeper lamina propria are smaller with more processes and weak acid phosphatase activity. There are also differences in phenotypes of macrophages between the small and large intestine; in the former, smaller cells with weaker acid phosphatase activity but stronger ATPase activity prevail, compared to the latter (2). It is likely that these phenotypic differences are related to their different functional requirements which may be related to differences in the luminal contents.

STUDIES ON MACROPHAGES IN SITU IN ACTIVE IBD

In active IBD, macrophages with strong acid phosphatase activity are present throughout the lamina propria, and also in the submucosa in Crohn's disease. Using a panel of monoclonal antibodies, three subpopulations of macrophages have been identified that are present in the lamina propria of the mucosa with active IBD but absent or only rarely present in the normal mucosa. These subpopulations were identified with the monoclonal antibodies RFD9 to FcRIII (CD16) and to interleukin-2 (IL-2) receptor.

**RFD9 positive macrophages:** In the normal intestine, this antibody only labelled macrophages in the germinal centres of Peyer's patches. In active IBD, RFD9 positive macrophages were seen in the lamina propria (3-5) and were present in clusters, especially in Crohn's disease. RFD9 positive cells have also been seen in the inflamed mucosa of pouches (constructed after colectomy for ulcerative colitis) (6) but not in celiac disease (7) or bacterial colitis. Thus, studies to date suggest that RFD9 positive macrophages are seen only in the lamina propria of the mucosa with active IBD. It can be postulated that the clusters of RFD9 positive macrophages in Crohn's disease may go on to form granulomata.

**Macrophages expressing FcRIII:** Surface labelling of macrophages with the anti-FcRIII antibody (CD16) was seen in the lamina propria of mucosa with active IBD (but not normal mucosa).

Animal studies suggest that cells expressing these low affinity IgG receptors may be involved in taking up and clearing immune complexes (8), and the mucosal macrophages in IBD may be performing a similar function.

**Macrophages expressing receptors for IL-2:** Using an enhanced alkaline phosphatase antialkaline phosphatase technique, many IL-2 receptor positive cells have been demonstrated in the mucosa with active IBD (9). These cells had morphological appearances of lymphocytes and macrophages. Identity of the latter was confirmed by studies on isolated cells (which also showed that these cells are in an enhanced state of activation). Using a similar technique, Choy et al have subsequently also reported the presence of IL-2 receptor positive cells in the mucosa with active ulcerative colitis and Crohn's disease and have confirmed the identity of the other population of cells to be T cells (10).

**Studies on Crohn's granulomata:** Heterogeneity of macrophages in and around granulomata has also been demonstrated (11). Epithelial cells and giant cells were labelled with the antibody RFD9 but not RFD7, whereas macrophages in the surrounding lamina propria were usually RFD7-positive but RFD9 negative. The epithelioid cells expressed IL-2 receptors and were strongly acid phosphate activity positive. Double staining studies showed that the epithelioid cells were closely associated with CD4 positive (helper) T cells whereas CD8 positive cells were much fewer in number and located mainly at the periphery. Thus, Crohn's granulomata comprise collections of cells of distinct phenotypes which are likely to be constantly interacting with each other.

FUNCTIONAL STUDIES ON ISOLATED MACROPHAGES

**Respiratory burst activity:** Compared to a resting cell, an activated macrophage has an enhanced capacity to perform a number of functions which include secretion of oxygen radicals and enzymes (such as neutral proteases and acid hydrolases). There is an associated increased expression of major histocompatibility complex (MHC) class II molecules and downregulation of mannose receptors on the cell surface. Activation of macrophages may occur in response to microorganisms and their products or interferon gamma (secreted by T cells) and allows the cell to mediate antimicrobial and cytotoxic effects (12).

In order to determine the activation phenotype of intestinal macrophages, the capacity of the isolated cells to undergo a respiratory burst (as assessed by conversion of the dye nitroblue tetrazolium to a blue brown reaction product) was studied (13).

Oposened zymosan and phorbol myristate acetate were used to trigger the release of oxygen radicals. The majority (80% or more) of isolated normal intestinal macrophages did not demonstrate release of oxygen radicals. In contrast, a significantly increased proportion of macrophages from the intestine of patients with IBD were able to undergo a respiratory burst, suggesting that they were activated.

When the normal intestinal macrophages were stimulated with interferon-gamma (normally a very potent activator of macrophages), significant proportions of the cells were still unable to release oxygen radicals. This
suggests that the majority of the normal intestinal tissue macrophages are downregulated with respect to this function and that the cells with increased capacity to release oxygen radicals are derived predominantly from monocytes which have recently migrated into the mucosa. Oxygen radicals produced by activated macrophages may also contribute to tissue damage in the mucosa.

**Antigen presenting activity:** Studies in mice have shown that dendritic cells are the most potent antigen presenting cells and that these cells may be distinct from macrophages. In order to characterize cells with potent antigen presenting activity in the human intestinal mucosa, isolated monocellular cells were studied (14). Their capacity to induce proliferation of highly purified, resting, allogeneic, peripheral blood T cells was used to assess antigen presenting activity. This activity in isolated monocellular cells was reduced upon depletion of macrophages (by adherence to fibronectin and panning using a macrophage specific monoclonal antibody). In contrast, the fibronectin adherent cells (which are enriched for macrophages) had enhanced antigen presenting activity. During the mixed lymphocyte reactions, clusters were shown to contain cells with a dendritic morphology which were closely associated with proliferating T cells. The cells with dendritic morphology were strongly positive for human lymphocyte antigen DR (HLA-DR) and also expressed antigens specific for macrophages. It was concluded therefore that cells with potent antigen presenting activity in the intestinal mucosa have characteristics of both dendritic cells and macrophages.

Cells isolated from mucosa with active IBD were shown to have enhanced antigen presenting activity compared to mononuclear cells from normal mucosa.

**IL-1β production:** IL-1 is a cytokine with a wide range of biological properties which may play an important role in the pathogenesis of IBD (15). Monocytes and macrophages are the main source of this cytokine of which IL-1β is the predominant secreted from.

In vitro culture of mononuclear cells isolated from intestinal mucosa with active IBD have been shown to produce significantly greater amounts of IL-1β than cells from normal mucosa (16). Depletion studies (by panning) showed that macrophages were the predominant producers of this cytokine in the intestine. Culture of mononuclear cells from normal mucosa in the presence of lipopolysaccharide (a very potent stimulant of IL-1 production by monocytes) did not result in any increase in the production of IL-1β, whereas there was an increase in the amount of the cytokine produced by cells from the inflamed mucosa. As for studies on respiratory burst activity, this suggests that the normal intestinal tissue macrophages are downregulated and that the enhanced production of IL-1β in IBD is derived from monocytes which have recently migrated into the mucosa.

Studies on tissue homogenates have confirmed enhanced in vivo production of IL-1β in the mucosa of patients with active IBD (17, 18).

**Studies on IL-6 and IL-8:** Recent studies on IL-6 and IL-8 (which can be secreted macrophages) in IBD suggest that macrophages may have different functional capacities in ulcerative colitis and Crohn’s disease. Higher circulating levels of IL-6 have been found in active Crohn’s disease compared to ulcerative colitis by three groups independently (19-21).

Higher tissue levels of IL-8 have been demonstrated in the mucosa of patients with active ulcerative colitis compared to active Crohn’s disease. Patients with active ulcerative colitis also had high circulating levels of antibodies to IL-8, but this was not the case in patients with active Crohn’s disease where the levels were similar to normal controls (22). IL-8 is a very potent chemoattractant for neutrophils and the high mucosal levels in active ulcerative colitis may explain the characteristic predominance of neutrophils in this condition. The role of macrophages in the differential production of these cytokines in ulcerative colitis and Crohn’s disease remains to be determined.

REFERENCES


12. Adams DO, Hamilton TA. The cell
biology of macrophage activation. Ann
Respiratory burst activity of intestinal
macrophages in normal and
inflammatory bowel disease. Gut
14. Mahida YR, Wu K, Jewell DP.
Characterization of antigen presenting
activity of mononuclear cells isolated
from normal and inflammatory bowel
disease colon and ileum. Immunology
15. Cominelli F, Nast CC, Clark BD,
Schindler R, Llerena R, Eysselin VE,
Thompson RC, Dinarello CA.
Interleukin-1 (IL1) gene expression,
synthesis and effect of specific receptor
blockade in rabbit immune complex
16. Mahida YR, Wu K, Jewell DP.
Enhanced production of interleukin 1β
by mononuclear cells isolated from
mucosa with active ulcerative colitis or
17. Mahida YR, Lamming CED, Gallagher
A, Hawthorne AB, Hawkey CJ.
5-aminosalicylic acid is a potent
inhibitor of IL1β production in organ
culture of colonic biopsies from
patients with inflammatory bowel
18. Ligumsky M, Simon PL, Karmeli FC,
Rachmilewitz D. Role of interleukin-1
in inflammatory bowel disease -
enhanced production during active
19. Mahida YR, Kurlak L, Gallagher A,
Hawkey CJ. High circulating levels of
interleukin 6 in active Crohn’s disease
but not ulcerative colitis. Gut
20. Gross V, Andus T, Caesar I, Roth M,
Scholmerich J. Evidence for
continuous stimulation of interleu­
kin-6 production in Crohn’s disease.
21. Lobo AJ, Jones SC, Evans SW, Banks
R, Rathbone BJ, Axon ATR. Plasma
interleukin-6 in inflammatory bowel
22. Mahida YR, Ceska M, Effenberger F,
Kurlac L, Lindley I, Hawkey CJ.
Enhanced synthesis of NAPI/IL8 in
active ulcerative colitis. Clin Sci